Biosimilars in Brazil: The Beginning of an Era of Broader Access

Journals Menu

Follow SCIRP

	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journal of Cancer Therapy

ISSN Print: 2151-1934
ISSN Online: 2151-1942
www.scirp.org/journal/jct
E-mail: jct@scirp.org

Citations

Journals Menu

"Biosimilars in Brazil: The Beginning of an Era of Broader Access"
written by Marcio Debiasi, Franklin Fernandes Pimentel, Paula Juliana Seadi Pereira, Carlos H. Barrios,
published by Journal of Cancer Therapy, Vol.8 No.9, 2017

has been cited by the following article(s):

Google Scholar
CrossRef

[1]	Cancer treatment with biosimilar drugs: A review
	Cancer …, 2024

[2]	Perfil de compras federais de anticorpos monoclonais oncológicos no Brasil: análise de 2015 a 2019
	2021

[3]	Evaluation of the Regulatory Requirements for Development and Approval of Biosimilar Medicines in the BRICS-TM Countries: Improving Patients' Access
	2021

[4]	O papel do farmacêutico na discussão sobre intercambialidade no tratamento de câncer de mama com Trastuzumabe
	2021

[5]	Biofármacos no Brasil: uma revisão do processo de regulamentação/Biopharmaceuticals in Brazil: a review of the regulatory process
	2020

[6]	Biopharmaceutical Innovation on Pharmerging Countries: A Quantitative Analysis and Scenario Prediction
	2020

[7]	Comparability Pathway for the Approval of Similar Biologics with Respect to Reference Biologics in Europe and Brazil
	2020

[8]	Impact of follow-on biological products in the Brazilian health system Posted 05/01/2018
	2018

[9]	Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
	mAbs, 2018

[10]	Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
	Pharmaceutical Medicine, 2018

[11]	The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars.
	Oncologist, 2018

[12]	The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars
	2018

[1]	Cancer treatment with biosimilar drugs: A review Cancer Innovation, 2024 DOI:10.1002/cai2.115

[2]	Cancer treatment with biosimilar drugs: A review Cancer Innovation, 2024 DOI:10.1002/cai2.115

[3]	Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America mAbs, 2018 DOI:10.1080/19420862.2018.1484977

[4]	Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab Pharmaceutical Medicine, 2018 DOI:10.1007/s40290-018-0247-5

Follow SCIRP

	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journal of Cancer Therapy

Journal of Cancer Therapy

Journals Menu

Home

About SCIRP

Service

Policies